Course: The Latest Updates on the Role of HER2-Low and HER2-Ultralow in Treatment Selection for Metastatic Breast Cancer
CME Credits: 1.00
Released: 2026-04-17
The landscape regarding diagnosis and treatment of human epidermal growth factor receptor 2 (HER2)-low and -ultralow mBC is evolving. Our expert faculty will interpret the latest clinical trial data on antibody-drug conjugates (ADCs) and discuss how to apply updated guideline recommendations for optimal treatment selection and manage ADC-specific adverse events (AEs). These evidence-based strategies tailored to HER2-low and HER2-ultralow expression profiles will enhance clinical decision-making and ultimately improve patient outcomes.
Upon completion of this activity, participants should be better able to:
View Full Course